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SUMMARY
Fifty patients whose sera contained a speckled antinuclearantibody (ANA) were
interviewed and examined to determine if there was any relationship between
their clinical manifestations and thepresence ofcertain serological markers. The
results suggest that speckled ANA is usually found in patients with definite
connective tissue diseases, but a significant minority have incomplete or early
stages ofthese diseases. Characterisation ofthe antibody to extractable nuclear
antigen (ENA) and otherserological markers does not normally assist in making
a clinical diagnosis, but the detection of a speckled ANA should prompt further
investigation and careful follow up.
INTRODUCTION
Autoantibodies to nuclear antigens can be detected in a variety ofways. Immuno-
fluorescent staining of tissue specimens and cultured cells can reveal antibodies
reactive with nuclear components and various patterns of staining, i.e.
homogeneous, nucleolar, speckled-patterns have been identified and found to be
diagnostically useful. In addition immunochemical tests using antigens extracted
from cell nuclei (extractable nuclear antigens; ENA) can be used to identify a
number of these antinuclear antibodies. A number of groups have reported the
clinical significance ofantibodies toextractable nuclearantigens (ENA), butthese
studies have generally been carried out on highly selected groups of patients
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drawn from specialist clinics.1 2,3 This selection tends to introduce a bias in favour
of the speciality concerned. In an attempt to overcome this problem, we have
examined the clinical and laboratory features of patients whose sera were
received in a routine diagnostic immunology laboratory and gave a speckled
antinuclear antibody staining pattern at a titre ofone in 80 or greater, when tested
by indirect immunofluorescence.
MATERIALS AND METHODS
Patients
Fifty consecutive patients on whom data were complete and who had significant
titres of speckled antinuclear antibody (ANA) were selected for study. Of these
50 patients, 42 were female and eight male with a mean age of 45 years (range:
15 to 87 years). The duration of disease symptoms was between two and 31
years. Each patient was reviewed in person by a clinician (ACF, JDMcC or AJT)
who completed a detailed questionnaire recording the time and nature of the
onset of clinical symptoms and the course of the illness. Patients were examined
for signs of disease with particular reference to the locomotor system and
connective tissues. Systemic lupus erythematosus (SLE), progressive systemic
sclerosis (PSS) and rheumatoid arthritis (RA) were all diagnosed according to
criteria of the American Rheumatism Association (ARA).4, 5'6 The results of all
previous investigations were recorded and a blood sample was taken for
estimation of antibodies to double-stranded deoxyribonucleic acid (ds DNA),
single-stranded deoxyribonucleic acid (ss DNA), histone, centromere, cardiolipin
and extractable nuclear antigens (ENA). Rheumatoid factor (RF), complement
components C3 and C4, immunoglobulins G, A and M were also measured.
Laboratory methods
Antibodies giving acharacteristic speckled ANA pattern were detected byindirect
immunofluorescence using 5 pm cryostat sections of rat composite tissue as
substrate and fluorescein conjugated rabbit immunoglobulin to human kappa
and lambda chains. The titresofantibodies inindividual G and M immunoglobulin
classes were determined using both fluorescein conjugated rabbit immuno-
globulins to human IgG and IgM.
Antibodies to extractable nuclear antigens (anti-ribonucleoprotein, - Sm, - Ro
and - La) were detected and identified using counterimmunoelectrophoresis
(CIE) and various saline cellular extracts as previously described." 2' 7, 8 Antibody
levels to double-stranded (ds) DNA were assayed using the Farr technique and a
level of ds DNA antibody activity greater than 25 units/ml was considered as a
positive result. Antibody to denatured single-stranded (ss) DNA was detected by
CIE.9 Anticentromere antibody was detected by indirect immunofluorescence
using HEp 2 cultured cells as antigen.'0 Positive reference sera for antibodies to
extractable nuclear antigens (ENA), ds DNA and centromere were obtained from
the Centers for Disease Control, Atlanta, Georgia, USA. Antibody to histones was
determined using indirect immunofluorescence and an acid-extraction histone-
reconstitution assay." Rheumatoid factor (RF) was assayed using the differential
agglutination test12 employing rabbit IgG as antigen and a quantitative latex assay
which employed human IgG as antigen. The WHO International Reference
preparation for rheumatoid factors was employed and a level of 30 IU/ml or
greater was considered positive for this study. Antibody to cardiolipin was
determined by a positive reaction against the Venereal Disease Research
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Laboratory (VDRL) antigen with an accompanying negative reaction with the
fluorescent treponemal antibody absorption test (FTA-ABS). Measurements of
immunoglobulins G, A and M and complement C3 and C4 were assayed by laser
nephelometry using internal standards (Beckman, UK).
Statistical analysis
Clinical and laboratory data were analysed using the 'Statistical Package for the
Social Sciences' on a Vax computer at the Queen's University of Belfast. The
statistical methods applied were the chi-squared test, the independent t-test and
its non-parametric equivalent, the Mann-Whitney U test.
RESULTS
The majority of patients in the study group (40%) were diagnosed as systemic
lupus erythematosus (SLE) with progressive systemic sclerosis (PSS) as the
second most common diagnosis (18%). Patients with other connective tissue
disorders comprised a further 22% of the total. The remainder (20%) had
miscellaneous disorders, which included pulmonary fibrosis (with and without
systemic hypertension), thrombocytopenic purpura, haemolytic anaemia and
a bleeding tendency. Two patients had hypergammaglobulinaemia (IgG) and
one had systemic hypertension (Table 1). None of these patients was on any
TABLE I
Clinical diagnosis
Diagnosis Number Number in group
Systemic lupus erythematosus 15
with Sj6gren's syndrome 3
with recurrent deep vein thrombosis 1 20 (40%)
with cutaneous vasculitis 1
Progressive systemic sclerosis 4
with Sj6gren's syndrome 2
with Sjogren's syndrome and
rheumatoid arthritis 1
with rheumatoid arthritis 1 9 (18%)
with polymyositis 1
Mixed picture 4 4 (8%)
Vasculitis (small vessel) 2
with Sjogren's syndrome 1 3 (6%)
Rheumatoid arthritis 1
with Sj6gren's syndrome 2 3 (6%)
Polymyositis 1 1 (2%)
Miscellaneous
Pulmonary fibrosis 4
Haematological disorders 3 10 (20%)
Hypergammaglobulinaemia 2
Hypertension 1
Total 50 50 (100%)
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medication known to be associated with drug-induced lupus and in all cases
antibodies to histones were not detected. Sjogren's syndrome, which was
diagnosed clinically, was found in 18% of the patients. Sixty-two per cent of
patients were receiving immunosuppressive therapy at the time of their review.
These individuals were distributed evenly throughout the clinical groups
irrespective of their antibody profile. Renal involvement was associated with
antibody to ds DNA (50%) and decreased levels ofC3 (67%). Twenty per cent of
the patients with SLE and 22% of those with PSS had laboratory evidence of
renal disease.
Antibody profiles
All the patients in the study had antibody to extractable nuclear antigens (ENA).
The specificities of these antibodies are shown in Table 11. The incidence of
antibodies to ribonucleoprotein (RNP) alone, Ro and La, RNP, Ro and La, and
Sm antigens were 54%, 24%, 14% and 8% respectively. Patients with antibody
to Sm always had antibody to RNP and sometimes Ro. Antibodies to Sm and ds
DNA were detected only in patients with SLE, whereas anti-RNP and anti-Ro with
anti-La were present in a similar wide range of conditions. An important
exception was PSS where all nine patients had antibody to RNP but none had
antibody to Ro or La. All of these nine patients also had ss DNA antibody in their
sera. Patients in the miscellaneous group had a higher percentage of antibodies
to the mixture of RNP, Ro and La. Of the nine patients with Sjogren's syndrome,
five (56%) had antibody to Ro and La. None of the 50 patients tested had
antibodies to the VDRL antigen or to centromere. The SLE group had the highest
incidence of IgG elevation and complement depression.
TABLE II
Antibody profiles ofpatients grouped according to clinical groups
RNP Ro/La
Clinical group ds DNA only only RNP/Ro/La* Sm**
(patient numbers) (8) (27) (12) (7) (4)
Systemic lupus
erythematosus 100 33 50 14 100
Progressive systemic
sclerosis 0 26 0 29 0
Mixed picture 0 7 8 14 0
Vasculitis 0 4 17 0 0
Rheumatoid arthritis 0 7 8 0 0
Polymyositis 0 4 0 0 0
Miscellaneous 0 19 17 43 0
Figures within the table are percentages
*Antibody present to at least two of these antigens
* *Sm positive (two patients Sm + RNP, two patients Sm, RNP + Ro)
Statistical findings
In view ofthe large number ofpossible associations ofclinical features and serum
markers, a comprehensive listing ofthese is not given - most were notsignificant.
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Some of the more positive associations are shown in Table II1. If values below
the 1 % level are considered to be clinically significant, then only xerostomia and
the presence of an LE skin r4sh were significantly associated with particular
antibodies. Therewas nosignificantassociation between thepresenceofantibody
to RNP and Raynaud's phenomenon or the presence of antibodies to Sm antigen
and renal or central nervous system disease.
TABLE III
Association between clinical features and the presence ofserum markers
Associated
Clinical features serum * P value
marker
Eye problems at presentation La 0.05
Joint features at review RNP <0.05
Signs/symptoms at any time:-
1. Involvement of cervical spine (C1-3) RF < 0.05
2. Involvement of cervical spine (C4-7) RF < 0.05
3. Myalgia RNP < 0.05
4. Dysphagia RNP <0.05
5. Radiological evidence of abnormal
oesophageal motility RNP <0.05
6. Xerophthalmia Ro < 0.05
7. Xerostomia Ro < 0.01
8. Xerostomia La < 0.01*
9. Discoid LE skin rash Sm < 0.01
*Serum marker present at time of review
**Clinically significant
DISCUSSION
In general, these results are in keeping with previously published work. However,
our patients had a much wider range of diagnoses than those drawn purely
from rheumatological departments. Connective tissue disorders were diagnosed
in 80% of patients but the remaining 20% had a variety of immunological,
pulmonary, cardiovascular and haematological complaints. All the patients
whose sera gave a speckled ANA staining pattern had antibody to ENA.
Antibodies were not associated with a particular clinical diagnosis, with the
exception ofthe association ofSLEwith antibodies to ds DNA or Sm. Antibody to
RNP alone was detected in all nine patients with PSS. This is in contrast to a
number of studies where very few of these patients (0-5%) had antibody to
RNP.13, 14 In a multicentre study on patients with PSS, serum antibodies to RNP
characterised individuals with a PSS-overlap syndrome but did not occur in those
with PSS alone.5 In contrast, the follow-up to Sharp's original paper on mixed
connective tissue disease reported that 45% ofthose with antibody to RNPfinally
developed PSS.15 The nine patients in our study with PSS were among the oldest
in the group and had the longest disease duration, so the length offollow-up may
explain these discrepancies. Antibodies to Ro and La were detected in 56% of
patients with Sj6gren's syndrome which is consistent with previous reports. In
© The Ulster Medical Society, 1986.
116Speckled antinuclear antibodies 117
contrast, however, these antibodies were detected in 33% of patients with SLE
who did not have Sj6gren's syndrome. Other studies have shown antibody to La
in only 2 - 3% of such patients.3 16
The attempt to find statistically significant associations between clinical features
and serological markers proved fruitless. Only xerostomia and a discoid LE skin
rash were significantly associated with particular antibodies and these are unlikely
to be of practical value. Despite this, our study demonstrates that the vast
majority of patients with a speckled ANA do have significant disease and that the
detection of this serological marker should prompt further investigation.
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